VANCOUVER, May 11, 2018 /CNW/ - INVICTUS MD STRATEGIES
CORP. ("Invictus" or the "Company") (TSXV: GENE; OTC: IVITF; FRA:
8IS1) is pleased to announce that cannabis from the company's
AB Laboratories Inc. (AB Labs) is now available for
purchase through Canopy Growth Corporation's (TSX: WEED) Tweed Main
Street online store and to-date AB Labs has transferred 172 KG of
product to Canopy.
The strain Super Critical is available now as part of Tweed's
elite CraftGrow line, and AB Labs anticipates shipping their other
strains in the near future.
"Canadian medical cannabis patients value product diversity and
we're committed to offering them an industry leading curated lineup
from Tweed and our CraftGrow partners," said Mark Zekulin, President, Canopy Growth. "We're
excited to welcome AB Labs product as the newest CraftGrow addition
to the Tweed Main Street online store".
"The Canadian cannabis industry is diverse, dynamic and
thriving, with valuable partnerships being forged every day," said
Invictus founder and CEO Dan Kriznic. "Our collaboration with
Canopy has already been enormously fruitful and rewarding. We look
forward to working closely with this model of entrepreneurial
fitness and efficiency as Canada's
commercial cannabis market develops in coming months and years. I'm
pleased to report that Invictus remains on track for achieving its
substantial cultivation and harvest goals across 2018, and delivers
more and more strains and cannabis volume into Canada's thriving consumer marketplace as
Canada approaches legalization of
the adult market. To further accommodate this the Company has
developed a multifaceted sales strategy aimed to target each
channel for sales and distribution such as establishing supply
agreements and product calls with provincial governments and
licensed producers, developing retail storefronts across
Western Canada, and continuing to
focus on the medical cannabis sector."
Tweed's highly curated CraftGrow line works only with top
producers cultivating Canada's
finest cannabis, and AB Labs is honored to have been the second
cultivator to successfully transfer cannabis products to be sold
though the e-commerce platform.
The Super Critical strain from AB Labs available on the platform
is a high-yielding 50/50 hybrid of sativa and indica, a mix of Big
Bud, Skunk and White Widow. The combination of exceptional yield
plus superb flower makes it a favorite among growers.
AB Labs continues to make continuous progress on its 40,000
square foot Phase 2 facility, which once completed AB Labs will
total 56,000 square foot of production capability. To-date in
Phase 2 the interior demolition has been completed, cleaned and
sanitized and all upgrades to the electrical and HVAC systems have
also been completed. Construction of the mezzanine level has begun
and overall progress is according to plan.
About Invictus
Invictus owns and operates cannabis companies in Canada with the vision of producing a variety
of high quality and low cost cannabis products and strains to the
global market place as regulations permit. Gene Simmons, music legend and media mogul,
conveys the vision of Invictus as the Chief Evangelist Officer.
Invictus operates two cannabis production sites under the Access
to Cannabis for Medical Purposes Regulations ("ACMPR") in
Canada and has over 95,000 square
feet of cannabis production capacity at the licensed production
sites. The Company's wholly owned subsidiary Acreage Pharms
Ltd. ("Acreage Pharms"), located in West-Central Alberta on
150 acres, has approximately 40,000 square feet of cannabis ready
production with its recently completed Phase 2 expansion. The
Company intends on expanding to 120,000 square feet by the end of
2018 once Phase 3 is complete.
Invictus also owns 50% of AB Laboratories Inc. ("AB
Labs"), a licensed producer under the ACMPR located in
Hamilton, Ontario. AB Labs
currently operates in a 16,000 square foot facility and recently
acquired a facility adjacent to the existing property that will
allow for a total of 56,000 square feet of cultivation space
expected to be ready for production by June
2018. During the first quarter of 2018 AB Labs submitted a
secondary license to Health Canada for a nearby property on 100
acres under the name AB Ventures Inc. ("AB Ventures").
Combined, the licensed producers owned by Invictus expect to
have approximately 200,000 square feet of cannabis production
capacity by the end of 2018 and 520,000 square feet of cannabis
production capacity by the end of 2019.
In addition to the ACMPR licenses, the Company has an 82.5%
investment in Future Harvest Development Ltd. a high quality
Fertilizer and Nutrients manufacturer based in Kelowna, British Columbia that has been in
operation for over 20 years under the brand Plant Life Products and
Holland Secret.
For more information, please visit www.invictus-md.com.
On Behalf of the Board,
Dan Kriznic
Chairman & CEO
Larry Heinzlmeir
Vice President, Marketing & Communications
604-537-8676
In the United States
Terry Wills
twills@willscom.com
310-877-1458
Cautionary Note Regarding Forward-Looking Statements: This
release includes certain statements and information that may
constitute forward-looking information within the meaning of
applicable Canadian securities laws or forward-looking statements
within the meaning of the United States Private Securities
Litigation Reform Act of 1995. All statements in this news release,
other than statements of historical facts, including statements
regarding future estimates, plans, objectives, timing, assumptions
or expectations of future performance, including the development of
additional cannabis strains, the potential production capacity of
AB Labs, AB Ventures and Acreage Pharms, the completion of AB
Ventures and Acreage Pharms' production facilities, the granting of
regulatory approval and anticipated timing of AB Labs reaching full
production capacity, the granting of AB Labs secondary license, the
granting of a sales license under the ACMPR to Acreage Pharms,
expected sales of inventory and the legalization of the
recreational use of marijuana in Canada in 2018 are forward-looking statements
and contain forward-looking information. Generally, forward-looking
statements and information can be identified by the use of
forward-looking terminology such as "intends" or "anticipates", or
variations of such words and phrases or statements that certain
actions, events or results "may", "could", "should", "would" or
"occur". Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release,
including that Acreage Pharms will be successful in developing
additional cannabis strains, that AB Labs will be successful in
reaching its potential production capacity on the timeline expected
by the Company, AB Ventures and Acreage Pharms' production
facilities will be completed as anticipated, regulatory approval
will be granted as anticipated, AB Labs will reach full production
capacity on the timeline anticipated by the Company, AB Labs will
be granted its secondary license on the terms and timeline
anticipated by the Company, no unforeseen construction delays will
be experienced, Acreage Pharms will be granted its sales license
under the ACMPR on the terms and timeline anticipated by the
Company, expected sales of inventory will be met and the
legalization of the recreational use of marijuana in Canada will occur as expected. These
forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information.
Important factors that may cause actual results to vary, include,
without limitation, Acreage Pharms will not be successful in
developing additional cannabis strains or, if developed, such
strains will not have the benefits anticipated by the Company, AB
Labs will not be successful in reaching its potential production
capacity, AB Ventures and Acreage Pharms' production facilities
will not be completed as anticipated, construction delays,
regulatory approval will not be granted as anticipated and
therefore, the anticipated timing of AB Labs reaching full
production capacity will be delayed, AB Labs not be granted their
secondary license, Acreage Pharms will not be granted its
sales license under the ACMPR, licenses or approvals being granted
on terms or timelines that are materially worse than expected by
the Company, expected sales of inventory will not be met and the
legalization of the recreational use of marijuana in Canada will not occur at all or as expected.
Although management of the Company has attempted to identify
important factors that could cause actual results to differ
materially from those contained in forward-looking statements or
forward-looking information, there may be other factors that cause
results not to be as anticipated, estimated or intended. There can
be no assurance that such statements will prove to be accurate, as
actual results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on forward-looking statements and
forward-looking information. Readers are cautioned that reliance on
such information may not be appropriate for other purposes. The
Company does not undertake to update any forward-looking statement,
forward-looking information or financial out-look that are
incorporated by reference herein, except in accordance with
applicable securities laws. We seek safe harbor.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View original
content:http://www.prnewswire.com/news-releases/cannabis-strain-from-invictus-ab-laboratories-now-for-sale-on-canopy-growth-corporations-tweed-sales-platform-300646974.html
SOURCE Invictus MD Strategies